The Pharmaceutical Benefits Advisory Committee (PBAC) will assess a new treatment for generalised MG patients in early 2024 and we have the opportunity to make a consumer submission. This means we can share our lived experience with national decision makers and help to ensure new treatment options are available, accessible, and affordable.
Your response to the following questions will help inform the submission to be put forward by the MAA on behalf of our patient community.